Isomorphic Labs Completes $210 Million Series B Financing, Led by Thrive Capital
Alphabet-backed AI biotech company Isomorphic Labs announced the completion of a Series B financing round worth about $210 million. Cross-source verification confirms that Thrive Capital led the round, with participation from Alphabet/GV, Temasek, CapitalG, and the U.K. AI Fund/UK Sovereign AI Fund. The use of proceeds points to the expansion of its AI drug-design platform, but the claim that the funds will also advance internal programs into clinical trials appears only in the event summary and cannot be confirmed from the sources provided.